Pipeline

UbiVac and collaborators are in various stages of research and clinical trials with a pipeline of immunotherapeutic products that include DRibble (DPV-001 and DPV-002), Nano Particle and CMV Vector.

Autophagosome “Dribble” Immunotherapy Platform

Product Indication Status
DPV-001 Definitively-treated stage IIIA/B NSCLC Phase II enrolling
DPV-001 Advanced Prostate Cancer Pilot study enrolling
DPV-001 + anti-PD-1 Advanced NSCLC Phase I/II opens 1st Qtr 2018
DPV-001 + anti-OX40 Breast Cancer Phase I/II opens 2nd Qtr 2018
DPV-003HPV HPV+ Cancers Preclinical
DPV-004 Oral Cancer Preclinical

NanoParticle Immunotherapy Platform

Product Indication Status
NP-001 HPV+ HNSCC and cervical cancer Preclinical

Spread defective (SdCMV) Immunotherapy Platform

Product Indication Status
sdCMV-001 Melanoma Preclinical
sdCMV-002 HPV + cancers Preclinical